Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Chemotherapy-induced neuropathy is a serious clinical problem caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib; these drugs cause different pathologic insults to neurons. Keywords: chemotherapy-induced peripheral neuropathy (CIPN), rrandomised controlled trial, drugs, treatment, efficacy, safety, systematic review. 1 Introduction. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the main dose-limiting side effects of neurotoxic anticancer drugs. Specifically, Cohort Identification and Descriptive Analysis (CIDA) Level-1 queries were executed to identify the cohorts, ascertain exposures (i.e., to chemotherapy) and outcomes (i.e., a peripheral neuropathy code or a pharmacy dispensing of gabapentin, pregabalin, or duloxetine), and produce unadjusted incidence rates. Peripheral neuropathies in cancer patients are most often due to neurotoxic chemotherapeutic agents, the so-called chemotherapy-induced peripheral neuropathy (CIPN); less frequently they occur as paraneoplastic, immune-mediated, or neoplastic neuropathies. Chemotherapy-induced peripheral neuropathy (CIPN) is a progressive, enduring, and often irre-versible adverse effect of many antineoplastic agents, among which sensory abnormities are common and the most suffering issues. The pathogenesis of CIPN Compared with the control group, gabapentin therapy led to a statistically significant better response in patients of each baseline neurotoxicity group. Conclusions: Gabapentin monotherapy seems to be well tolerated and useful for the management of chemotherapy-induced neuropathic pain. This study was conducted to investigate the efficacy and safety of gabapentin monotherapy in the management of chemotherapy-induced neuropathic pain. Patients. Seventy-five cancer patients who had previously received chemotherapy, and had experienced at least one symptom of neuropathic pain were included in the intervention group. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). For CIPN prevention, gabapentinoids show no significant benefits in reducing neuropathy among chemotherapy patients, with evidence being too weak to warrant their use without further study. Based on the current limited evidence, gabapentinoids seem to be beneficial in the treatment of CIPN, but more evidence is required to substantiate this. Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most disabling and demoralizing problems that arise for cancer survivors. When investigating symptoms of numbness, tingling, or pain in the extremities, it is critical to determine whether the problem is neuropathic, somatic, or mixed. Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) affects patients' quality of life and treatment effectiveness. Gabapentinoids, like gabapentin and pregabalin, are often used for CIPN treatment, but their efficacy and safety remain uncertain. An overview of neurologic complications with platinum and non-platinum chemotherapy drugs, and recommendations for dose modification for platinum and non-platinum chemotherapeutic drugs when neuropathy develops during therapy are provided elsewhere. Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and other specific agents. The combination of “chemotherapy-induced peripheral neuropathy” and each of the following keywords were used to search for CIPN treatment: “calcium and magnesium”, “goshajinkigan”, “duloxetine”, “vitamin B12”, “pregabalin”, “gabapentin”, and “pancreatic cancer”. On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Prevention of chemotherapy-induced peripheral neuropathy. 1.1 Clinicians should assess the risks and benefits of agents known to cause CIPN among patients with underlying neuropathy and with conditions that predispose to neuropathy such as diabetes and/or a family or personal history of When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory rather than motor and include reduced feeling and heightened sensitivity to pressure, pain, temperature, and touch. On the basis of these data, a multicenter, double-blind, placebo-controlled, crossover, randomized trial was conducted to evaluate the effect of gabapentin on symptoms of chemotherapy-induced peripheral neuropathy (CIPN). The aim of our study was to assess the presence of chemotherapy-induced peripheral neuropathy in ovarian cancer patients treated with first-line paclitaxel and carboplatin chemotherapy and evaluate the effectiveness of gabapentin in treatment of this condition. When peripheral neuropathy occurs due to chemotherapy treatment, it is termed Chemotherapy-induced peripheral neuropathy (CIPN) [1], [2], [5]. CIPN is a frequent adverse effect of anticancer agents most commonly presenting with sensory symptoms more than motor symptoms in a symmetrical “glove and stocking” distribution [3], [4], [5], [6].
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |